非瓣膜性房颤合并肝病患者直接口服抗凝药的使用与长期持续性
基于英国临床实践研究数据链构建2011–2020年非瓣膜性房颤合并肝病起始口服抗凝药的人群队列,共3167例,其中DOAC起始者2247例(71%)、VKA起始者920例(29%)。5年时DOAC起始者31%、VKA起始者9%仍持续用药,DOAC长期持续性高于VKA但总体仍偏低。
要点
- 合并肝病的非瓣膜性房颤患者多数起始DOAC治疗(71%)。
- 5年持续率DOAC为31%、VKA为9%,DOAC较高但总体仍低。
- 治疗中止前诊断为缺血性卒中或出血者很少。
核心结论
- 多数非瓣膜性房颤合并肝病患者起始DOAC治疗,DOAC长期持续性高于VKA但仍相对较低。
研究设计与样本
- 使用英国临床实践研究数据链构建2011–2020年起始口服抗凝药的非瓣膜性房颤合并肝病人群队列,共3167例。
- 采用logistic回归估计患者特征与起始DOAC vs VKA关联的OR及95%CI,采用Cox比例风险模型估计患者特征与VKA转换为DOAC vs 继续VKA关联的HR及95%CI。
- 评估DOAC vs VKA的5年治疗持续性,并分析治疗中止前是否发生缺血性卒中或出血。
主要发现
- 队列中DOAC起始者2247例(71%),VKA起始者920例(29%)。
- DOAC起始者较VKA起始者更可能有既往缺血性卒中(OR 1.44,95%CI 1.12–1.85),但较少使用抗血小板药(OR 0.66,95%CI 0.53–0.82)。
- 转换为DOAC者较继续VKA者更可能使用选择性5-羟色胺再摄取抑制剂(HR 1.64,95%CI 1.13–2.37)。
- 5年时DOAC起始者31%、VKA起始者9%仍持续治疗。
- 仅少数患者在治疗中止前被诊断为缺血性卒中或出血。
临床怎么用
- 对非瓣膜性房颤合并肝病患者选择DOAC时,应关注长期持续用药的随访与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We characterized the utilization and long-term treatment persistence of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF) and liver disease. METHOD: Using the UK Clinical Practice Research Datalink, we assembled a population-based cohort of NVAF patients with liver disease initiating oral anticoagulants between 2011 and 2020. Logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) of the association between patient characteristics and initiation of DOACs vs vitamin K antagonists (VKAs). Cox proportional hazards models estimated hazard ratios (HRs) and 95% CIs of the association between patient characteristics and the switch from VKAs to DOACs vs remaining on VKAs. We also assessed the 5-year treatment persistence with DOACs vs VKAs, and whether ischemic stroke or bleeding preceded treatment discontinuation. RESULTS: Our cohort included 3167 NVAF patients with liver disease initiating DOACs (n = 2247, 71%) or VKAs (n = 920, 29%). Initiators of DOACs were more likely to have prior ischemic stroke (OR 1.44, 95% CI 1.12-1.85) than VKA initiators but less likely to have used antiplatelet agents (OR 0.66, 95% CI 0.53-0.82). Patients switching to DOACs were more likely to have used selective serotonin reuptake inhibitors (HR 1.64, 95% CI 1.13-2.37) than those remaining on VKAs. At 5 years, 31% of DOAC initiators and 9% of VKA initiators remained persistent. Only few patients were diagnosed with ischemic stroke or bleeding prior to treatment discontinuation. CONCLUSION: Most NVAF patients with liver disease initiated treatment with DOACs. Long-term persistence with DOACs was higher than with VKAs but remained relatively low.
引用
- Douros A, Cui Y, Platt RW, et al. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. Br J Clin Pharmacol. 2021. PMID: 34409636. doi:10.1111/bcp.15046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。